SubsidieMeestersUnraveling Parkinson´s disease diagnostic
UNMASK aims to validate a non-invasive, olfaction-inspired technology for fast Parkinson's disease diagnostics, addressing the need for timely detection and reducing its social and economic burden.
Projectdetails
Introduction
Parkinson's disease (PD) is a progressive, chronic, and debilitating neurodegenerative disease for which there is no cure and no diagnostic test available. About 10 million people live with PD worldwide (1.2 million in Europe), and this number is expected to double by 2030 due to the aging population.
Social and Economic Impact
PD has a high social and economic burden, and there is a need to improve PD timely detection and diagnosis, especially in young people.
Project Objectives
UNMASK aims to validate the technological and business feasibility of the olfaction-inspired technology developed in the ERC Starting Grant SCENT by establishing the proof-of-concept for the non-invasive and fast PD diagnostics.
Approach
To accomplish this, we will approach the project from both technical and business perspectives, with:
- A perfect synergy between the research and business teams
- Close contact with clinical collaborators and stakeholders
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-7-2024 |
| Einddatum | 31-12-2025 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- NOVA ID FCT - ASSOCIACAO PARA A INOVACAO E DESENVOLVIMENTO DA FCTpenvoerder
- DAY ONE SOCIETA A RESPONSABILITA LIMITATA
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Signal-enhanced MRI contrast agents for neurodegenerationThis project aims to develop and validate new magnetic resonance technologies for early, non-invasive diagnosis of neurodegenerative diseases using metabolic contrast agents. | ERC Proof of... | € 150.000 | 2022 | Details |
Improving quality of life of Parkinson’s disease patients by Quantitative Cognitive TestingThe project aims to enhance Parkinson's disease therapy by using Quantitative Cognitive Testing to assess cognitive functions, improve patient quality of life, and reduce healthcare costs. | ERC Proof of... | € 150.000 | 2023 | Details |
A web-platform interfaced software for spectroscopic molecular characterization and early diagnosis of Parkinson's diseaseThe SEMISOFT project aims to develop software and a web platform for molecular characterization and early Parkinson's diagnosis using advanced spectral analysis and machine learning techniques. | ERC Proof of... | € 150.000 | 2022 | Details |
Novel small molecule attenuator of neuroinflammation in Parkinson’s DiseaseNEUROSHIELD aims to develop a novel small molecule targeting neuroinflammation in Parkinson's disease to improve patient quality of life and address a significant treatment gap. | ERC Proof of... | € 150.000 | 2025 | Details |
Metal-Organic-Framework Kinetic Array for Diabetes DetectionThis project aims to develop a novel sensor using metal-organic frameworks to selectively detect volatile organic compounds in breath for non-invasive diabetes diagnosis. | ERC Proof of... | € 150.000 | 2024 | Details |
Signal-enhanced MRI contrast agents for neurodegeneration
This project aims to develop and validate new magnetic resonance technologies for early, non-invasive diagnosis of neurodegenerative diseases using metabolic contrast agents.
Improving quality of life of Parkinson’s disease patients by Quantitative Cognitive Testing
The project aims to enhance Parkinson's disease therapy by using Quantitative Cognitive Testing to assess cognitive functions, improve patient quality of life, and reduce healthcare costs.
A web-platform interfaced software for spectroscopic molecular characterization and early diagnosis of Parkinson's disease
The SEMISOFT project aims to develop software and a web platform for molecular characterization and early Parkinson's diagnosis using advanced spectral analysis and machine learning techniques.
Novel small molecule attenuator of neuroinflammation in Parkinson’s Disease
NEUROSHIELD aims to develop a novel small molecule targeting neuroinflammation in Parkinson's disease to improve patient quality of life and address a significant treatment gap.
Metal-Organic-Framework Kinetic Array for Diabetes Detection
This project aims to develop a novel sensor using metal-organic frameworks to selectively detect volatile organic compounds in breath for non-invasive diabetes diagnosis.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Revolutionary therapeutic treatment for stopping progression of Parkinson's diseaseHerantis is developing HER-096, a novel pharmaceutical aimed at modifying Parkinson's disease pathology to alleviate symptoms and reduce the societal burden of the condition. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Smart Electronic Olfaction for Body Odor DiagnosticsSMELLODI aims to digitize and synthesize olfactory information for remote disease diagnostics and assist individuals with olfactory disorders using advanced sensor technology and machine learning. | EIC Pathfinder | € 3.263.781 | 2022 | Details |
Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative DiseaseThe project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens. | EIC Pathfinder | € 2.992.203 | 2022 | Details |
Datadriven beslismodel voor Parkinson patiëntenCue2Walk ontwikkelt een datadriven beslismodel om snel te bepalen of Parkinson-patiënten baat hebben bij hun draagbare apparaat, ter ondersteuning van hun mobiliteit en zorgverbetering. | Mkb-innovati... | € 20.000 | 2023 | Details |
Real time Liver disease early diagnosis through exhaled Volatile Organic Compounds sensingDiaNose aims to revolutionize NAFLD diagnostics with a cost-effective, hand-held device using AI to classify breath chemical signatures, achieving >90% accuracy for improved patient outcomes. | EIC Transition | € 2.499.875 | 2024 | Details |
Revolutionary therapeutic treatment for stopping progression of Parkinson's disease
Herantis is developing HER-096, a novel pharmaceutical aimed at modifying Parkinson's disease pathology to alleviate symptoms and reduce the societal burden of the condition.
Smart Electronic Olfaction for Body Odor Diagnostics
SMELLODI aims to digitize and synthesize olfactory information for remote disease diagnostics and assist individuals with olfactory disorders using advanced sensor technology and machine learning.
Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative Disease
The project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens.
Datadriven beslismodel voor Parkinson patiënten
Cue2Walk ontwikkelt een datadriven beslismodel om snel te bepalen of Parkinson-patiënten baat hebben bij hun draagbare apparaat, ter ondersteuning van hun mobiliteit en zorgverbetering.
Real time Liver disease early diagnosis through exhaled Volatile Organic Compounds sensing
DiaNose aims to revolutionize NAFLD diagnostics with a cost-effective, hand-held device using AI to classify breath chemical signatures, achieving >90% accuracy for improved patient outcomes.